Clinical Trial Update: A Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (GASMOTIN™) in Healthy Adult Human Subjects Under Fasting Conditions [Phase 1]

View source ↗

Summary

Phase 1 study comparing two GR107719B mosapride formulations to a 5 mg tablet of reference mosapride citrate (GASMOTIN) to assess relative bioavailability in fa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastritis

Drugs mentioned

• GASMOTIN (mosapride citrate)
• GR107719B Formulation 1 (mosapride)
• GR107719B Formulation 2 (mosapride)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Gastritis | Phase 1 | Status: COMPLETED